Related Experiment Video

Updated: May 8, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.4K

Ceftazidime/Avibactam for the Treatment of Infections in Children: A Case Series of Real-World Use

Almudena Castro-Frontiñán1,2, Luis Manuel Prieto-Tato3,4,5,6, Jose Manuel Caro-Teller7,2

  • 1Pharmacy Department, Hospital 12 de Octubre, Madrid, Spain.

Paediatric Drugs
|February 28, 2025
PubMed

Insights

Ceftazidime/avibactam (CAZ/AVI) shows effectiveness in treating pediatric urinary tract infections and other serious bacterial infections. This review highlights its adequate effectiveness and safety in children, supporting its use in pediatric infectious disease management.

Area of Science:

  • Pediatric Infectious Diseases
  • Antimicrobial Stewardship
  • Clinical Pharmacology

Background:

  • Ceftazidime/avibactam (CAZ/AVI) is approved for children aged 3 months+ for UTIs and IAIs.
  • Limited published data exists on CAZ/AVI use in pediatric populations.
  • Carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas pose significant treatment challenges.

Purpose of the Study:

  • To review existing literature on CAZ/AVI use in children.
  • To summarize efficacy, adverse effects, and pharmacokinetics of CAZ/AVI in pediatric patients.
  • To describe real-world experience with CAZ/AVI in a tertiary pediatric hospital.

Main Methods:

  • Literature search for CAZ/AVI use in children, including clinical trials and case series.
  • Analysis of 22 treatment episodes in 14 pediatric patients at a tertiary hospital (up to March 2023).
  • Review of clinical conditions, treatment strategies (targeted vs. empirical), and outcomes.

Main Results:

  • CAZ/AVI demonstrated adequate effectiveness across various pediatric infections, including UTI, bacteremia, and sepsis.
  • The drug was used as both targeted and empirical therapy.
  • No treatment discontinuations due to adverse effects were reported, indicating a favorable safety profile.

Conclusions:

  • CAZ/AVI is an effective and safe option for treating serious bacterial infections in children.
  • The review supports the use of CAZ/AVI in pediatric infectious disease management, especially for resistant pathogens.
  • Further real-world data collection is valuable for optimizing pediatric antimicrobial therapy.

More Related Videos

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.4K
Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

6.8K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
261
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
94
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
180
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.6K
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
96
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
145